[
  {
    "ts": "2025-12-23T06:10:03+00:00",
    "headline": "Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return",
    "summary": "Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and profitability quietly improve. See our latest analysis for Bio-Techne. At around $58.96, Bio-Techne is still nursing a weak 1 year total shareholder return of roughly negative 18 percent. However, the 3 month share price return in the low double digits hints that sentiment is stabilizing as investors...",
    "url": "https://finance.yahoo.com/news/bio-techne-tech-revisiting-valuation-061003271.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "840004e2-6c69-30cf-962f-755787e3e115",
      "content": {
        "id": "840004e2-6c69-30cf-962f-755787e3e115",
        "contentType": "STORY",
        "title": "Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return",
        "description": "",
        "summary": "Why Bio-Techne Is Back on Investors Radar Bio-Techne (TECH) has been drifting after a tough year, but recent gains over the past 3 months suggest investors are rethinking the story as growth and profitability quietly improve. See our latest analysis for Bio-Techne. At around $58.96, Bio-Techne is still nursing a weak 1 year total shareholder return of roughly negative 18 percent. However, the 3 month share price return in the low double digits hints that sentiment is stabilizing as investors...",
        "pubDate": "2025-12-23T06:10:03Z",
        "displayTime": "2025-12-23T06:10:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-tech-revisiting-valuation-061003271.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bio-techne-tech-revisiting-valuation-061003271.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]